Literature DB >> 16921495

Possible role of preproghrelin gene polymorphisms in susceptibility to bulimia nervosa.

Tetsuya Ando1, Gen Komaki, Tetsuro Naruo, Kenjiro Okabe, Masato Takii, Keisuke Kawai, Fujiko Konjiki, Michiko Takei, Takakazu Oka, Kaori Takeuchi, Akinori Masuda, Norio Ozaki, Hiroyuki Suematsu, Kenzo Denda, Nobuo Kurokawa, Kotarou Itakura, Chikara Yamaguchi, Masaki Kono, Tatsuyo Suzuki, Yoshikatsu Nakai, Aya Nishizono-Maher, Masanori Koide, Ken Murakami, Kiyohide Nagamine, Yuichiro Tomita, Kazuyoshi Ookuma, Kazumi Tomita, Eita Tonai, Akira Ooshima, Toshio Ishikawa, Yuhei Ichimaru.   

Abstract

Previous investigations have suggested that ghrelin, an endogenous orexigenic peptide, is involved in the pathology of eating disorders. We conducted a study to determine whether any preproghrelin gene polymorphisms are associated with eating disorders. Three hundred thirty-six eating disorder patients, including 131 anorexia nervosa (AN)-restricting types (AN-R), 97 AN-binge eating/purging types (AN-BP) and 108 bulimia nervosa (BN)-purging types (BN-P), and 300 healthy control subjects participated in the study. Genotyping was performed to determine the polymorphisms present, and with this information, linkage disequilibrium (LD) between the markers was analyzed and the distributions of the genotypes, the allele frequencies, and the haplotype frequencies were compared between the groups. The Leu72Met (408 C > A) (rs696217) polymorphism in exon 2 and the 3056 T > C (rs2075356) polymorphism in intron 2 were in LD (D' = 0.902, r2 = 0.454). Both polymorphisms were significantly associated with BN-P (allele-wise: P = 0.0410, odds ratio (OR) = 1.48; P = 0.0035, OR = 1.63, for Leu72Met and 3056 T > C, respectively). In addition, we observed a significant increase in the frequency of the haplotype Met72-3056C in BN-P patients (P = 0.0059, OR = 1.71). Our findings suggest that the Leu72Met (408 C > A) and the 3056 T > C polymorphisms of the preproghrelin gene are associated with susceptibility to BN-P. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16921495     DOI: 10.1002/ajmg.b.30387

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  12 in total

Review 1.  Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa.

Authors:  A Torsello; F Brambilla; L Tamiazzo; I Bulgarelli; D Rapetti; E Bresciani; V Locatelli
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

2.  Genetics and Epigenetics of Eating Disorders.

Authors:  Zeynep Yilmaz; J Andrew Hardaway; Cynthia M Bulik
Journal:  Adv Genomics Genet       Date:  2015-03-10

3.  The Genetics of Anorexia Nervosa: Current Findings and Future Perspectives.

Authors:  Andrea Poyastro Pinheiro; Tammy Root; Cynthia M Bulik
Journal:  Int J Child Adolesc health       Date:  2009

4.  Serotonin-induced decrease of intracellular Ca(2+) release in platelets of bulimic patients normalizes during treatment.

Authors:  Lars Wöckel; Florian Daniel Zepf; Sabrina Koch; Anikó-Eva Meyer-Keitel; Martin H Schmidt
Journal:  J Neural Transm (Vienna)       Date:  2008-12-10       Impact factor: 3.575

5.  The role of leptin, melanocortin, and neurotrophin system genes on body weight in anorexia nervosa and bulimia nervosa.

Authors:  Zeynep Yilmaz; Allan S Kaplan; Arun K Tiwari; Robert D Levitan; Sara Piran; Andrew W Bergen; Walter H Kaye; Hakon Hakonarson; Kai Wang; Wade H Berrettini; Harry A Brandt; Cynthia M Bulik; Steven Crawford; Scott Crow; Manfred M Fichter; Katherine A Halmi; Craig L Johnson; Pamela K Keel; Kelly L Klump; Pierre Magistretti; James E Mitchell; Michael Strober; Laura M Thornton; Janet Treasure; D Blake Woodside; Joanne Knight; James L Kennedy
Journal:  J Psychiatr Res       Date:  2014-04-16       Impact factor: 4.791

6.  Associations between ghrelin and ghrelin receptor polymorphisms and cancer in Caucasian populations: a meta-analysis.

Authors:  Noel A Pabalan; Inge Seim; Hamdi Jarjanazi; Lisa K Chopin
Journal:  BMC Genet       Date:  2014-11-07       Impact factor: 2.797

7.  Leu72Met and Other Intronic Polymorphisms in the GHRL and GHSR Genes Are Not Associated with Type 2 Diabetes Mellitus, Insulin Resistance, or Serum Ghrelin Levels in a Saudi Population.

Authors:  Faris Elbahi Joatar; Ali Ahmed Al Qarni; Muhalab E Ali; Abdulaziz Al Masaud; Abdirashid M Shire; Nagalla Das; Khalid Gumaa; Hayder A Giha
Journal:  Endocrinol Metab (Seoul)       Date:  2017-09

8.  Eating Disorder Neuroimaging Initiative (EDNI): a multicentre prospective cohort study protocol for elucidating the neural effects of cognitive-behavioural therapy for eating disorders.

Authors:  Sayo Hamatani; Yoshiyuki Hirano; Ayako Sugawara; Masanori Isobe; Naoki Kodama; Kazufumi Yoshihara; Yoshiya Moriguchi; Tetsuya Ando; Yuka Endo; Jumpei Takahashi; Nobuhiro Nohara; Tsunehiko Takamura; Hiroaki Hori; Tomomi Noda; Keima Tose; Keita Watanabe; Hiroaki Adachi; Motoharu Gondo; Shu Takakura; Shin Fukudo; Eiji Shimizu; Kazuhiro Yoshiuchi; Yasuhiro Sato; Atsushi Sekiguchi
Journal:  BMJ Open       Date:  2021-01-25       Impact factor: 2.692

9.  A natural variant of obestatin, Q90L, inhibits ghrelin's action on food intake and GH secretion and targets NPY and GHRH neurons in mice.

Authors:  Rim Hassouna; Philippe Zizzari; Odile Viltart; Seung-Kwon Yang; Robert Gardette; Catherine Videau; Emilio Badoer; Jacques Epelbaum; Virginie Tolle
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

10.  Psychological and weight-related characteristics of patients with anorexia nervosa-restricting type who later develop bulimia nervosa.

Authors:  Hiroki Nishimura; Gen Komaki; Tetsuya Ando; Toshihiro Nakahara; Takakazu Oka; Keisuke Kawai; Toshihiko Nagata; Aya Nishizono; Yuri Okamoto; Kenjiro Okabe; Masanori Koide; Chikara Yamaguchi; Satoshi Saito; Kazuyoshi Ohkuma; Katsutaro Nagata; Tetsuro Naruo; Masato Takii; Nobuo Kiriike; Toshio Ishikawa
Journal:  Biopsychosoc Med       Date:  2008-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.